Vimseltinib

Vimseltinib (DCC-3014) is a c-FMS (CSF-IR) and c-Kit dual inhibitor extracted from patent WO2014145025A2, Compound Example 10, has IC50s of [1]. Vimseltinib has certain oral bioavailability[2].

Product Specifications

CAS Number

[1628606-05-2]

Product Name Alternative

DCC-3014

UNSPSC

12352005

Hazard Statement

H315, H319

Target

C-Fms; c-Kit

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/c-kit-in-5.html

Purity

99.94

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N(C)C(NC(C)C)=NC=C1C2=NC(C)=C(OC3=CC(C4=CN(C)N=C4)=NC=C3)C=C2

Molecular Formula

C23H25N7O2

Molecular Weight

431.49

Precautions

H315, H319

References & Citations

[1]Yumi Ahn, et al. 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities. WO2014145025A2.|[2]Kisielewska K, et al. An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors. Expert Rev Anticancer Ther. 2025 Apr;25 (4) :327-335.